Anavex Life Sciences Corporation

-0.09 (-1.50%)
Products, Regulatory

Anavex Life Sciences Announces Positive Results On Phase 2 Clinical Trial In Parkinson’S Disease Dementia

Published: 10/15/2020 11:40 GMT
Anavex Life Sciences Corp (AVXL) - Anavex Life Sciences Announces Positive Results From Proof of Concept Controlled Phase 2 Clinical Trial Evaluating Anavex®2-73 (blarcamesine) in Parkinson’s Disease Dementia.
Anavex Life Sciences Corp - Study Found That Anavex2-73 (blarcamesine) Was Safe and Well Tolerated in Oral Doses Up to 50 Mg Once Daily.
Anavex Life Sciences - Results Show Statistically Significant Improvements in Cognitive Drug Research (cdr) Computerized Assessment System Analysis.
Anavex - After Completing Trial, Participants Were Able to Enroll in Voluntary 48-week Open-label Extension Study, Anavex 2-73-pdd-ep-001.